Ser366
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser366  -  EEF2K (human)

Site Information
sPQVRtLsGSRPPLL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447827

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 4 , 20 ) , [32P] ATP in vitro ( 4 ) , immunoprecipitation ( 24 ) , mass spectrometry ( 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 23 ) , mass spectrometry (in vitro) ( 4 ) , mutation of modification site ( 3 ) , phospho-antibody ( 2 , 4 , 5 , 7 , 20 , 21 , 22 , 23 , 24 ) , phosphopeptide mapping ( 4 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 21 , 22 , 23 , 24 )
Disease tissue studied:
glioblastoma multiforme ( 3 ) , glioma ( 3 ) , cervical cancer ( 2 , 21 , 22 ) , cervical squamous cell carcinoma ( 2 , 21 , 22 ) , gastric cancer ( 6 ) , gastric carcinoma ( 6 ) , lung cancer ( 1 , 6 , 7 ) , non-small cell lung cancer ( 1 , 7 ) , non-small cell lung adenocarcinoma ( 1 ) , non-small cell squamous cell lung carcinoma ( 6 ) , neuroblastoma ( 5 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 4 , 12 , 13 , 14 , 24 ) , A549 (pulmonary) ( 1 ) , E.coli (bacterial) ( 4 ) , ES (stem) ( 24 ) , HeLa (cervical) ( 20 , 23 ) , K562 (erythroid) ( 15 ) , KB (squamous) ( 2 , 21 , 22 ) , MKN-45 (gastric) ( 6 , 8 , 9 , 10 , 11 , 18 , 19 ) , myocyte-heart ( 22 ) , NCI-H1703 (squamous) ( 6 , 16 , 17 ) , NCI-H460 (pulmonary) ( 7 ) , SH-SY5Y (neural crest) ( 5 ) , T98G (glial) ( 3 )

Upstream Regulation
Regulatory protein:
EEF2K (human) ( 4 )
Putative in vivo kinases:
p70S6K (human) ( 24 ) , p90RSK (human) ( 24 )
Kinases, in vitro:
EEF2K (human) ( 4 ) , p70S6K (human) ( 24 ) , P70S6KB (human) ( 24 ) , p90RSK (human) ( 24 )
Treatments:
2-deoxyglucose ( 4 , 7 , 21 , 22 ) , cpTOME ( 4 ) , glucose ( 5 ) , glucose_starvation ( 1 ) , IGF-1 ( 24 ) , insulin ( 2 , 21 ) , low_glucose ( 5 ) , LY294002 ( 24 ) , NKH_477 ( 4 ) , PD184352 ( 24 ) , PF-4708671 ( 2 ) , phorbol_ester ( 24 ) , rapamycin ( 2 , 21 , 24 ) , Ro31-8220 ( 21 ) , serum_starvation ( 1 ) , thapsigargin ( 3 ) , U0126 ( 21 , 24 ) , wortmannin ( 21 )

Downstream Regulation
Effects of modification on EEF2K:
enzymatic activity, induced ( 4 )
Effects of modification on biological processes:
autophagy, inhibited ( 3 )

References 

1

Xiao M, et al. (2020) The eEF2 kinase-induced STAT3 inactivation inhibits lung cancer cell proliferation by phosphorylation of PKM2. Cell Commun Signal 18, 25
32054489   Curated Info

2

Wang X, et al. (2014) Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling. Mol Cell Biol 34, 4088-103
25182533   Curated Info

3

Cheng Y, et al. (2013) Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. Autophagy 9, 208-19
23182879   Curated Info

4

Pyr Dit Ruys S, et al. (2012) Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase. Biochem J 442, 681-92
22216903   Curated Info

5

Karyo R, et al. (2010) Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. Mol Cell Neurosci 45, 449-55
20708687   Curated Info

6

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

7

Zhong D, et al. (2009) The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R. J Biol Chem 284, 23225-33
19574224   Curated Info

8

Moritz A (2009) CST Curation Set: 7298; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

9

Moritz A (2009) CST Curation Set: 7296; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

10

Moritz A (2009) CST Curation Set: 7295; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

11

Moritz A (2009) CST Curation Set: 7297; Year: 2009; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

12

Guo A (2009) CST Curation Set: 6057; Year: 2009; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

13

Guo A (2009) CST Curation Set: 6055; Year: 2009; Biosample/Treatment: cell line, 293/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

14

Guo A (2009) CST Curation Set: 6056; Year: 2009; Biosample/Treatment: cell line, 293/Torin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

15

Moritz A (2007) CST Curation Set: 3207; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

16

Moritz A (2007) CST Curation Set: 2938; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

17

Moritz A (2007) CST Curation Set: 2939; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

18

Moritz A (2007) CST Curation Set: 2942; Year: 2007; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

19

Moritz A (2007) CST Curation Set: 2943; Year: 2007; Biosample/Treatment: cell line, MKN-45/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

20

Roberts EC, et al. (2006) Identification of G2/M targets for the MAP kinase pathway by functional proteomics. Proteomics 6, 4541-53
16858730   Curated Info

21

Browne GJ, Proud CG (2004) A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24, 2986-97
15024086   Curated Info

22

Browne GJ, Finn SG, Proud CG (2004) Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279, 12220-31
14709557   Curated Info

23

Knebel A, Haydon CE, Morrice N, Cohen P (2002) Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J 367, 525-32
12171600   Curated Info

24

Wang X, et al. (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20, 4370-9
11500364   Curated Info